A team of Caltech engineers has developed a technique for inkjet printing arrays of special nanoparticles that enables the mass production of long-lasting wearable sweat sensors. These sensors could be used to monitor a variety of biomarkers, such as vitamins, hormones, metabolites, and medications, in real time, providing patients and their physicians with the ability to continually follow changes in the levels of those molecules. (Image: Caltech)

A team of Caltech engineers has developed a technique for inkjet printing arrays of special nanoparticles that enables the mass production of long-lasting wearable sweat sensors. These sensors could be used to monitor a variety of biomarkers, such as vitamins, hormones, metabolites, and medications, in real time, providing patients and their physicians with the ability to continually follow changes in the levels of those molecules.

Wearable biosensors that incorporate the new nanoparticles have been successfully used to monitor metabolites in patients suffering from long COVID and the levels of chemotherapy drugs in cancer patients at City of Hope in Duarte, CA.

“These are just two examples of what is possible,” said Wei Gao, Professor of Medical Engineering in the Andrew and Peggy Cherng Department of Medical Engineering at Caltech. “There are many chronic conditions and their biomarkers that these sensors now give us the possibility to monitor continuously and noninvasively,” said Gao, who is the corresponding author on a paper in the journal Nature Materials describing the new technique.

Gao and his team describe the nanoparticles as core–shell cubic nanoparticles. The cubes are formed in a solution that includes the molecule that the researchers want to track — for example, vitamin C. As the monomers spontaneously assemble to form a polymer, the target molecule — vitamin C — is trapped inside the cubic nanoparticles. Next, a solvent is used to specifically remove the vitamin C molecules, leaving behind a molecularly imprinted polymer shell dotted with holes that have shapes exactly matching that of the vitamin C molecules — akin to artificial antibodies that selectively recognize the shapes of only particular molecules.

Importantly, in the new study, the researchers combine those specially formed polymers with a nanoparticle core made of nickel hexacyanoferrate (NiHCF). This material can be oxidized or reduced under an applied electrical voltage when in contact with human sweat or other bodily fluids. Returning to the vitamin C example, fluid will come into contact with the NiHCF core as long as the vitamin C–shaped holes are unoccupied, and this will generate an electrical signal.

When vitamin C molecules come into contact with the polymer, however, they slip into those holes, thus preventing sweat or other bodily fluids from making contact with the core. This weakens the electrical signal. The strength of the electrical signal, then, reveals just how much vitamin C is present.

“This core is critical. The nickel hexacyanoferrate core is highly stable, even in biological fluids, making these sensors ideal for long-term measurement,” said Gao, who is also a Heritage Medical Research Institute Investigator and a Ronald and JoAnne Willens Scholar.

The new core-shell nanoparticles are highly versatile and are used in printing sensor arrays that measure levels of multiple amino acids, metabolites, hormones, or drugs in sweat or bodily fluids simply by using multiple nanoparticle “inks” in a single array. For example, in the work described in the paper, the researchers printed out nanoparticles that bind to vitamin C along with other nanoparticles that bind to the amino acid tryptophan and creatinine, a biomarker commonly measured to see how well the kidneys are working. All of the nanoparticles were combined into one sensor that was then mass produced. These three molecules are of interest in studies of patients with long COVID. Similarly, the researchers printed out nanoparticles-based wearable sensors that were specific to three different antitumor drugs on individual sensors that were then tested on cancer patients at City of Hope.

“Demonstrating the potential of this technology, we were able to remotely monitor the amount of cancer drugs in the body at any given time,” Gao said. “This is pointing the way to the goal of dose personalization not only for cancer but for many other conditions as well.”

For more information, contact Wei Gao at This email address is being protected from spambots. You need JavaScript enabled to view it. or Kimm Fesenmaier at This email address is being protected from spambots. You need JavaScript enabled to view it.; 626-395-1217.



Magazine cover
Tech Briefs Magazine

This article first appeared in the October, 2025 issue of Tech Briefs Magazine (Vol. 49 No. 10).

Read more articles from this issue here.

Read more articles from the archives here.